112018-00-5

Basic information

• Product Name: Tebufelone
• Synonyms: Tebufelone;1-(3,5-Ditert-butyl-4-hydroxyphenyl)-5-hexyn-1-one;NE-11740
• CAS NO: 112018-00-5
• Molecular Formula: C₂₀H₂₈O₂
• Molecular Weight: 300.44
• Mol File: 112018-00-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 383.6°Cat760mmHg
• Flash Point: 163.8°C
• Appearance: /
• Density: 0.992g/cm³
• Vapor Pressure: 1.97E-06mmHg at 25°C
• Refractive Index: 1.515
• CAS DataBase Reference: Tebufelone(CAS DataBase Reference)
• NIST Chemistry Reference: Tebufelone(112018-00-5)
• EPA Substance Registry System: Tebufelone(112018-00-5)

Safety Data

• Hazardous Substances Data: 112018-00-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C20H28O2/c1-8-9-10-11-17(21)14-12-15(19(2,3)4)18(22)16(13-14)20(5,6)7/h1,12-13,22H,9-11H2,2-7H3

Upstream product

• 113101-57-8 4-(1'-hydroxy-5'-hexynyl)-2,6-di-tert-butylphenol 
• 128-39-2 2,6-di-tert-butylphenol 
• 55183-45-4 hex-5-in-carboxyl chloride 

Relevant articles and documents

Process for the preparation of certain substituted aromatic compounds

The present invention involves process for the preparation of compounds having the chemical structure: STR1 wherein Ar--H is an aromatic compound which is activated to an electrophilic attack, and wherein --Y is an aliphatic group having a labile moiety,

Novel anti-inflammatory agents, pharmaceutical compositions and methods for reducing inflammation

The present invention relates to novel specifically-substituted phenyl compounds, especially substituted di-tert-butyl phenol derivatives, which are effective as anti-inflammatory, analgesic and/or antipyretic agents. These phenyl compounds are substituted with a low molecular weight alkyl chain which terminates in a specific unsaturated functional group. These unsaturated functionalities are --C CH, C=CH2, C=C=CH2, and aldehydes in the form of their acetals. The present invention further relates to pharmaceutical compositions which contain an anti-inflammatory agent of the present invention and a pharmaceutically-acceptable carrier. Finally, the present invention relates to methods for treating diseases characterized by inflammation, such as rheumatoid arthritis and osteoarthritis, in humans or lower animals. Such methods comprise administering to a human or lower animal in need of such treatment a safe and effective amount of an anti-inflammatory agent or composition of the present invention.